B+
Bull case
20%
Probability
Target price
$0.65
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
BIAF
bioAffinityFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Rapid CyPath Lung volume and physician-adoption growth, ongoing enrollment in an 11-site longitudinal study, and expansion into asthma/COPD diagnostics provide a credible but early commercial and platform-development upside case. [#SEC-8K-2026-08-07]
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta 0.0.
What can break
Additional equity financing could create dilution and continued trading overhang.
Momentum
100
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.40 · Bull $0.65 · Bear $0.18Analysis 2026-08-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum100 · Δ7d -
Value41 · Δ7d 0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • Additional equity financing could create dilution and continued trading overhang.
- • Clinical validation may not translate into standard-of-care adoption or durable reimbursement.
- • The company remains a roughly $3.1 million market-cap microcap with a small revenue base, financing dependence, clinical-validation risk, and unresolved visibility around Nasdaq minimum-bid compliance identified in the prior baseline.
Catalyst clock
2026-08-13
Recent financing supports execution but adds dilution sensitivity
Lead driver: Value · See fundamentals
Momentum
100
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 99.9 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-14. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$0.40
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.18
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$3.18M
Beta
2.44
Shares Out
8.1M
P/E (TTM) · Derived
-0.0
P/S (TTM)
0.83
P/FCF (TTM) · Derived
-0.09
Rev YoY
+19.0%
EPS YoY
-87.3%
Gross Margin
+27.6%
Op Margin
-209.8%
Net Debt
-$5.29M
Current Ratio
1.44
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data